Humana (NYSE:HUM) had its price objective hoisted by analysts at JPMorgan Chase & Co. from $253.00 to $271.00 in a research report issued to clients and investors on Monday. The firm presently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 2.01% from the company’s current price.

HUM has been the subject of several other research reports. BMO Capital Markets lifted their price target on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $242.00 price target (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 19th. Morgan Stanley decreased their price objective on shares of Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a research note on Thursday, November 9th. Finally, Deutsche Bank raised their price objective on shares of Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $270.47.

Humana (HUM) traded up $0.33 on Monday, reaching $265.65. The company had a trading volume of 135,564 shares, compared to its average volume of 1,204,364. The stock has a market capitalization of $36,528.92, a price-to-earnings ratio of 15.91, a P/E/G ratio of 1.44 and a beta of 0.93. Humana has a 12 month low of $203.36 and a 12 month high of $293.35. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The company had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the business posted $2.34 earnings per share. analysts predict that Humana will post 13.85 earnings per share for the current year.

Humana announced that its board has authorized a stock buyback plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

In other news, SVP Brian P. Leclaire sold 1,679 shares of Humana stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the sale, the senior vice president now owns 9,888 shares of the company’s stock, valued at $2,432,151.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Timothy S. Huval sold 1,382 shares of Humana stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. Insiders have sold 10,115 shares of company stock valued at $2,501,627 in the last ninety days. Insiders own 0.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. WFG Advisors LP raised its stake in shares of Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares in the last quarter. Fieldpoint Private Securities LLC bought a new stake in shares of Humana during the third quarter valued at approximately $115,000. ClariVest Asset Management LLC bought a new stake in shares of Humana during the third quarter valued at approximately $144,000. Daiwa SB Investments Ltd. raised its stake in shares of Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after acquiring an additional 220 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Humana during the fourth quarter valued at approximately $204,000. 94.13% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/12/humanas-hum-hold-rating-reiterated-at-jpmorgan-chase-co.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.